ArticleAnnals of hematology2025

Brentuximab vedotin plus CHP-like regimen for the first-line treatment of PTCL patients: a real-world single center study.

Fangshu Guan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.